BR112012008173A2 - molécula de ligação específica de rsv - Google Patents

molécula de ligação específica de rsv

Info

Publication number
BR112012008173A2
BR112012008173A2 BR112012008173A BR112012008173A BR112012008173A2 BR 112012008173 A2 BR112012008173 A2 BR 112012008173A2 BR 112012008173 A BR112012008173 A BR 112012008173A BR 112012008173 A BR112012008173 A BR 112012008173A BR 112012008173 A2 BR112012008173 A2 BR 112012008173A2
Authority
BR
Brazil
Prior art keywords
specific binding
binding molecule
rsv
antibody
rsv specific
Prior art date
Application number
BR112012008173A
Other languages
English (en)
Other versions
BR112012008173B1 (pt
Inventor
Quirinus Bakker Adrianus
Yasuda Etsuko
Beaumont Tim
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of BR112012008173A2 publication Critical patent/BR112012008173A2/pt
Publication of BR112012008173B1 publication Critical patent/BR112012008173B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

molécula de ligação específica de rsv. a invenção fornece anticorpos e equivalentes funcionais dos mesmos que são capazes de ligar especificamente rsv. as sequências de ácido nucleico que encodifica o dito anticorpo, bem como a célula que produz anticorpos e métodos para produzir o dito anticorpo também são fornecidos.
BR112012008173-0A 2009-10-06 2009-10-06 Anticorpo monoclonal humano recombinante, sintético ou isolado ou uma parte funcional do mesmo que se liga especificamente à proteína f do vírus sincicial respiratório, sequência de ácido nucleico isolada ou um equivalente funcional da mesma, vetor, combinação, composição farmacêutica, usos dos mesmos e método para produzir um anticorpo ou parte funcional do mesmo BR112012008173B1 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/NL2009/050599 WO2011043643A1 (en) 2009-10-06 2009-10-06 Rsv-specific binding molecule

Publications (2)

Publication Number Publication Date
BR112012008173A2 true BR112012008173A2 (pt) 2017-10-10
BR112012008173B1 BR112012008173B1 (pt) 2021-12-07

Family

ID=42153917

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012008173-0A BR112012008173B1 (pt) 2009-10-06 2009-10-06 Anticorpo monoclonal humano recombinante, sintético ou isolado ou uma parte funcional do mesmo que se liga especificamente à proteína f do vírus sincicial respiratório, sequência de ácido nucleico isolada ou um equivalente funcional da mesma, vetor, combinação, composição farmacêutica, usos dos mesmos e método para produzir um anticorpo ou parte funcional do mesmo

Country Status (14)

Country Link
EP (1) EP2486053B1 (pt)
JP (1) JP5734988B2 (pt)
KR (1) KR101789343B1 (pt)
CN (1) CN102712692B (pt)
AU (1) AU2009353693B2 (pt)
BR (1) BR112012008173B1 (pt)
CA (1) CA2776249C (pt)
ES (1) ES2621458T3 (pt)
IL (1) IL219021A (pt)
MX (1) MX338063B (pt)
NZ (1) NZ599148A (pt)
RU (2) RU2540020C2 (pt)
WO (1) WO2011043643A1 (pt)
ZA (1) ZA201202502B (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007067032A1 (en) 2005-12-09 2007-06-14 Academisch Medisch Cemtrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
EP2540820B1 (en) 2005-12-09 2018-01-10 Academisch Medisch Centrum bij de Universiteit van Amsterdam Means and methods for influencing the stability of antibody producing cells
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
MX369784B (es) 2007-09-26 2019-11-21 Chugai Pharmaceutical Co Ltd Metodo de modificacion del punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
DK2708559T3 (en) 2008-04-11 2018-06-14 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of repeatedly binding two or more antigen molecules
CA2768207C (en) 2009-07-15 2019-12-03 Aimm Therapeutics B.V. Means and methods for producing high affinity antibodies
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
CN108715614A (zh) 2010-11-30 2018-10-30 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
RU2585153C2 (ru) 2010-12-02 2016-05-27 Аимм Терапьютикс Б.В. Средства и способы получения высокоаффинных антител
BR112013021526B1 (pt) 2011-02-25 2021-09-21 Chugai Seiyaku Kabushiki Kaisha Polipeptídio variante, métodos para manter ou diminuir as atividades de ligação a fcgriia (tipo r) e fcgriia (tipo h) e aumentar a atividade de ligação a fcgriib de um polipeptídio e para a supressão da produção de um anticorpo contra um polipeptídio compreendendo a região fc do anticorpo, métodos para a produção do referido polipeptídio com atividades de ligação mantidas ou diminuídas e aumentada e para a produção suprimida de um anticorpo, composição farmacêutica e uso de um polipeptídio
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
US9718876B2 (en) 2011-11-17 2017-08-01 Aimm Therapeutics B.V. RSV G protein specific antibodies
BR112014013081A2 (pt) 2011-11-30 2020-10-20 Chugai Seiyaku Kabushiki Kaisha veículo contendo fármaco em célula para formação de um complexo imune
CA2882272C (en) 2012-08-24 2023-08-29 Chugai Seiyaku Kabushiki Kaisha Fc.gamma.riib-specific fc region variant
AU2014212268B2 (en) 2013-02-01 2018-07-19 Medimmune, Llc Respiratory Syncytial Virus F protein epitopes
EP2970398B1 (en) 2013-03-13 2024-05-08 The United States of America, as Represented by The Secretary, Department of Health and Human Services Prefusion rsv f proteins and their use
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
JP6462599B2 (ja) 2013-03-15 2019-01-30 シャアメン ユニバーシティ Ｒｓｖ融合タンパク質のエピトープ及びそのエピトープを認識する抗体
AU2014250434B2 (en) 2013-04-02 2019-08-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
KR102188437B1 (ko) * 2014-01-15 2020-12-08 메디뮨 엘엘씨 Rsv 특이적 항체 및 이의 기능적 부위
BR112016017597A2 (pt) 2014-01-31 2017-08-08 Aimm Therapeutics Bv Métodos para produzir uma célula b, para selecionar pelo menos uma célula b, para produzir anticorpos específicos para um antígeno de interesse e para identificar pelo menos uma mutação na sequência de aminoácido da cadeia pesada e/ou cadeia leve de um anticorpo
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
CN106496324B (zh) 2015-11-30 2020-01-14 天津昊免生物技术有限公司 一种抗呼吸道合胞病毒的全人源抗体
PE20181354A1 (es) 2015-12-23 2018-08-22 Pfizer Mutantes de proteina f de rsv
TWI761453B (zh) * 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物
RU2713340C1 (ru) * 2018-12-28 2020-02-04 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт гриппа имени А.А. Смородинцева" Министерства здравоохранения Российской Федерации Моноклональные антитела, специфичные к различным штаммам респираторно-синцитиального вируса
WO2024069420A2 (en) 2022-09-29 2024-04-04 Pfizer Inc. Immunogenic compositions comprising an rsv f protein trimer
WO2024089634A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Immunogenic compositions against influenza and rsv
WO2024089633A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Rna molecules encoding rsv-f and vaccines containing them
WO2024127181A1 (en) 2022-12-11 2024-06-20 Pfizer Inc. Immunogenic compositions against influenza and rsv

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020182A (en) * 1996-07-12 2000-02-01 Connaught Laboratories Limited Subunit respiratory syncytial virus vaccine preparation
WO2004043989A2 (en) * 2002-11-07 2004-05-27 Medarex, Inc. Human monoclonal antibodies to heparanase
EP1720908A2 (en) * 2004-02-17 2006-11-15 Absalus, Inc. Super-humanized antibodies against respiratory syncytial virus
EP1997830A1 (en) * 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
WO2009030237A2 (en) * 2007-09-07 2009-03-12 Symphogen A/S Methods for recombinant manufacturing of anti-rsv antibodies
WO2009114815A1 (en) * 2008-03-13 2009-09-17 Dyax Corp Libraries of genetic packages comprising novel hc cdr3 designs

Also Published As

Publication number Publication date
CN102712692B (zh) 2014-12-31
EP2486053A1 (en) 2012-08-15
AU2009353693A1 (en) 2012-04-19
CN102712692A (zh) 2012-10-03
WO2011043643A1 (en) 2011-04-14
EP2486053B1 (en) 2017-01-18
MX338063B (es) 2016-04-01
JP2013506431A (ja) 2013-02-28
AU2009353693B2 (en) 2016-07-21
JP5734988B2 (ja) 2015-06-17
IL219021A (en) 2016-11-30
CA2776249A1 (en) 2011-04-14
ES2621458T3 (es) 2017-07-04
MX2012004086A (es) 2012-09-12
BR112012008173B1 (pt) 2021-12-07
CA2776249C (en) 2021-01-19
IL219021A0 (en) 2012-06-28
RU2540020C2 (ru) 2015-01-27
KR20120084755A (ko) 2012-07-30
RU2014151788A (ru) 2016-07-10
NZ599148A (en) 2014-08-29
RU2014151788A3 (pt) 2018-07-09
ZA201202502B (en) 2014-06-25
RU2012118636A (ru) 2013-11-20
KR101789343B1 (ko) 2017-10-23

Similar Documents

Publication Publication Date Title
BR112012008173A2 (pt) molécula de ligação específica de rsv
BRPI0923225A2 (pt) metodo para sintese de acidos nucleicos modificados no atomo de fosforo
MX350375B (es) Moleculas de union especificas de virus sincitial respiratorio y medios para producirlas.
BRPI0807756A2 (pt) Método para produzir um l-aminoácido.
BRPI0915886A2 (pt) método para amplificação direta a partir de amostras brutas de ácido nucléico
DK2121908T3 (da) Nukleinsyremolekyler, der koder for trunkeret alternansucrase
BRPI0822099A2 (pt) membro de ligação isolado, uso de um membro de ligação isolado, método parav tratar um distúrbio, molécula de ácido nucléico isolada, célula hospedeira, e, método para produzir um membro de ligação
BRPI0922106A2 (pt) anticorpo monoclonal isolado, molécula de ácido nucleico isolada, célula hospedeira, método para produzir um anticorpo monoclonal isolado, composição farmacêutica, e, uso da composição
EA201171325A1 (ru) Нуклеиновые кислоты, связывающиеся с гепсидином
WO2011079902A3 (en) Biological inhibitors of ror1 capable of inducing cell death
DK2831241T3 (da) Kunstige nukleinsyremolekyler til forbedret protein- eller peptidekspression.
EA201400709A1 (ru) Молекула биспецифического антитела
BRPI0906544A2 (pt) método de obtenção de informação a partir de células isoladas de interesse.
BRPI0918299A2 (pt) Método para produzir um l-aminoácido
BRPI0906795A2 (pt) Método para produzir um l-aminoácido
FI20085336A (fi) Menetelmä muurahaishapon talteenottamiseksi
BRPI0910458A2 (pt) catalisador para preparar acroleína ou ácido acrílico por reação de desidratação de glicerina e método para produzir o mesmo
UY31904A (es) Anticuerpos contra il-6 y sus usos
CL2008001682A1 (es) Metodos para el mejoramiento de plantas mediante el uso de informacion directa de secuencias de acidos nucleicos.
BRPI0811755A2 (pt) Amplificação específica de senquência de dna específicas de tumor.
BRPI0912755A2 (pt) Método para produzir um l-aminoácido
BRPI0813764A2 (pt) Processo para formação de haletos de carbonila alfa, beta-insaturados
BRPI0918654A2 (pt) processo para obtenção de combustíveis ou propelentes
BRPI0920435A2 (pt) processo para produzir gás de síntese de amônia.
DK2370206T3 (da) Katalysatorbærer, fremgangsmåde til fremstilling og anvendelse af denne

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/10/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 14A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2743 DE 01-08-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.